ADXS - Advaxis Inc.
TNS members were brought to attention OTC Exchange traded ADXS on upcoming Conference that ADXS will be presenting at $.13. TooNiceStocks saw the garner attention and ADXS climbed for 2 consecutive days, at one point reaching a peak of $.175, yielding a potiential 34.62% ROI.
Full TooNiceStocks Due Diligence Report Below
When I was doing my DD ADXS started to run after the news today on patent. I was blown away that I have been doing DD on this last week and good news comes out today! I was sooooo taken away back by this because you ALL KNOW I TOLD EVERYONE last week Im going to pick a monster pick.
Like how I alerted others to hidden biotechs, I rather get the young biotechs now and add them to my portfolio......
CHANGE OF GROUP STRATEGY, EVERYONE GET IN ON THIS, WE DO NOT TELL ANYONE JUST YET. PEOPLE START TO ACCUMULATE THEN WE WILL START TO UNLEASH TO THE PUBLIC. I"M TELLING YOU BELIEVE IN ME AND YOU WILL BE REWARDED.
Research:
I see another big bio potential in the horizon, however this bio isnt an overnight gainer (well now it might be after this post). It's a LONG play and I guarantee if you keep it in your portfolio within 1 month this will give you hopefully minimum 700%+ return on your money. I alerted people to CVM and HGSI in the early stages in their lives. Time to unleash ADXS flood gates. Added to that, I have been reading, hearing and speculating from other biotech investors that ADXS missed out on the 11th Annual Rodman & Renshaw Global Investment Conference in Sept. just like CVM for a reason, is this a coincidence? I think not, I have a feeling something juicy is brewing. CVM missed the conference and look at the news CVM just had on their H1N1 LEAPS technology drug and their pps now from .40s. ADXS I truly believe has a massive potential with updated data on their drugs, especially the Cervical one,ADXS11-001.
Their topline drug currently in their Pipeline,
Back to their Cervix cancer which Glaxo's chief executive Jean-Pierre Garnier, is reported as saying that Cervarix is a potential 'jewel' in its pipeline of new products, indicating
it could become one of the world's best-selling drugs. Some analysts believe the drug could be worth £2bn"
EXCELLENT DATA::
The median survival of cervix cancer patients who fail first line cytotoxic therapy, according to work conducted by the Gynecologic Oncology Group of the National Cancer
Institute, is 180 days. The median survival in this trial was 347 days. Historically, one (1) year survival in this disease is approximately 5%. In this study, one (1) year survival
was 53%. Four (4) of the thirteen (13) patients evaluable for efficacy (30%) experienced tumor reductions. One (1) patient experienced a greater than 30% reduction of her
tumor burden which is the criterion for a partial response. This patient received additional chemotherapy and surgery subsequent to ADXS11-001 and became tumor free
for over sixteen (16) months, and is still alive at 903 days. The two (2) patients who experienced fever requiring antibiotics are alive at 804 and 935 days.
I see ADXS slowly raising and BREAKING OUT before the 8th Annual BIO Investor Forum on October 28-29 at the Palace Hotel in San Francisco, Calif. where they plan to possibly present more updates on their drugs. In the recent weeks seems to me that investors have been slowly noticing ADXS from the slow upward trend indicated by the charts just look, please review yourself even before the news on the patent release yesterday, it has not had a DOWN DAY for 3 weeks!!!! GO CHECK YOURSELF!(SOMETHING IS BREWING)
The BIO conference is for "some of the most innovative therapeutic advances in the biotechnology sector. "Mark my words, I'm BULLISH gentlemen and women, I say $1.00pps (my estimate) in a year or two easily. I would keep this in my portfoilio for the long Run.
REMEMBER THIS IS A BIOTECH I DARE SHORTERS TO COME IN AND HOLD A SHORT POSITION OVERNIGHT...I DARE YOU......PLEASE DO SO!
-----------------
Industry Leaders to Discuss Investment Opportunities and Approaches to Sustaining and Leveraging Innovation WASHINGTON--(Business Wire)-- The Biotechnology Industry Organization (BIO) today announced the initial selection of 2009 presenting companies for the 8th Annual BIO Investor Forum on October 28-29 at the Palace Hotel in San Francisco, Calif. Companies identified to speak at this conference represent some of the most innovative therapeutic advances in the biotechnology sector. The BIO Investor Forum will feature over 110 company presentations from select late-stage private and emerging public biotech companies. Companies were chosen through a competitive screening process with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry. The advisory committee includes:
* Benjamin R. Bowen, Ph.D., Rodman & Renshaw, LLC
* Howard Furst, M.D., Deerfield Management
* John R. Leone, Paul Capital
* Graeme Martin, Ph.D., Takeda Research Investments, Inc.
* Evan McCulloch, CFA, Franklin Templeton Investments
* Oleg Nodelman, Biotechnology Value Fund, LP
* Heather Preston, M.D., TPG Biotech
* Bryan E. Roberts, Ph.D., Venrock
* Mark Schoenebaum, M.D., Deutsche Bank AG
* Chris Swindle, Wedbush PacGrow Life Sciences
* Paul Wagner, Ph.D., CFA, RCM Capital Management, LLC
"The BIO Investor Forum will feature senior management from biotech companies
that are poised for leadership status in highly competitive areas of therapeutic
innovation," said Alan Eisenberg, executive vice president, Emerging Companies &
Business Development at BIO. "The companies selected to speak in 2009 are
creating value through development-stage programs with near-term clinical
catalysts. These are the companies that will help drive the investment and deal
making in the life sciences sector and global innovation in healthcare."
Other recent news:
-New patent received:
The United States Patent and Trademark Office (USPTO) has granted and issued Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, patent 7,588,930 "Compositions and Methods for Enhancing Immunogenicity of Antigens." This patent expands the Company's intellectual property portfolio to cover another family of adjuvant proteins based upon the Lm protein Act-A.
-NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Incorporated (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) vaccine company, has been awarded a $210,000 grant from the US National Institute of Health (NIH) to develop a single bioengineered Lm vaccine to deliver two different antigen-adjuvant proteins.
-Advaxis, Inc. announced that it has entered into a collaboration with investigators at City of Hope, a biomedical research and treatment center, in the development of a vaccine for the treatment of certain forms of leukemia and lymphoma based upon the Company's Lm vaccine technology platform. City of Hope investigators are studying a vaccine provided by the Company directed against the tumor associated antigen WT-1. This molecule is observed to be over expressed in certain cancers of the blood as well as some solid tumors such as breast, pancreas and brain cancers, which makes it a target for a selective immune attack delivered via an Lm vector designed by the Company.
-Their Pipeline
-ADXS11-001 Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) and Head and Neck Cancer
-ADXS31-164 Breast Cancer
-ADXS31-142 Prostate Cancer
Advaxis is developing multiple platform approaches to the treatment of several cancers Included in the chart below which represent a market potential in excess of $10 billion
TooNiceStocks.com was not compensated, rather we have initiated our own independent research. As always read full disclaimer
